Mon, Jul 28, 2014, 10:26 AM EDT - U.S. Markets close in 5 hrs 34 mins

Recent

% | $
Click the to save as a favorite.

Insmed Incorporated Message Board

  • b_leaguered b_leaguered Nov 30, 2012 3:35 PM Flag

    Wedbush Says Insmed Weakness Could Be Related to Theravance's FDA Panel Decision

    "05:29 PM EST, 11/29/2012 (MidnightTrader) -- Theravance (THRX) today reported that the Anti-Infective Drugs Advisory Committee (AIDAC) of the U.S. Food and Drug Administration (FDA) has given the company a favorable response for its antibiotic VIBATIV (telavancin) for the treatment of nosocomial pneumonia due to susceptible isolates of Gram-positive microorganisms.
    In the company's meeting with the advisory committee, it received 6 (yes) votes and 9 (no) votes that the results it provided showed substantial evidence of the safety and effectiveness of VIBATIV for the requested indication; and 13 (yes) and 2 (no) votes that the results provided showed substantial evidence of the safety and effectiveness of VIBATIV for the treatment of nosocomial pneumonia when other alternatives are not suitable."
    Note: this is an injectable drug.
    If this is true, then someone must have factored in pneumonia as a potential future indication for Arikace.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Wedbush Says Insmed Weakness Could Be Related to Theravance's FDA Panel Decision

      By b_leaguered.Nov 30, 2012 3:35 PM
      "05:29 PM EST, 11/29/2012 (MidnightTrader) -- Theravance (THRX) today reported that the Anti-Infective Drugs Advisory Committee (AIDAC) of the U.S. Food and Drug Administration (FDA) has given the company a favorable response for its antibiotic VIBATIV (telavancin) for the treatment of nosocomial pneumonia due to susceptible isolates of Gram-positive microorganisms.
      In the company's meeting with the advisory committee, it received 6 (yes) votes and 9 (no) votes that the results it provided showed substantial evidence of the safety and effectiveness of VIBATIV for the requested indication; and 13 (yes) and 2 (no) votes that the results provided showed substantial evidence of the safety and effectiveness of VIBATIV for the treatment of nosocomial pneumonia when other alternatives are not suitable."
      Note: this is an injectable drug.
      If this is true, then someone must have factored in pneumonia as a potential future indication for Arikace.

    • Insmed is not mentioned in the body of the quote. Is the inference in the last sentence yours or Wedbush's?

    • At first glance of the chart, I thought it was Obama taking us over the so-called "fiscal cliff."

      Sentiment: Strong Buy

    • BL - Great Find, although I don't think it's a very good reason for an inhalation development company to fall, it is a better reason than because Terry told us iPLEX is dead!

    • Nice find, thanks.

 
INSM
17.02-0.48(-2.74%)10:26 AMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.